🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Immediate Release (IR) Formulation

Found 0 matching trials

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

PHASE3

To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) exte...

Status

Completed

Location

Xenoscience, Inc. (102)

Start Date

2018-11-06

Trial ID

NCT03670953

Treatments Being Tested

IR CD-LD IPX203 ER CD-LD Placebo Matching IPX203 Placebo Matching IR CD-LD

Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis

PHASE3

The objective of this study is to investigate if low doses of prednisone MR...

Status

Completed

Location

Research Site

Start Date

2004-08-31

Trial ID

NCT00146640

Treatments Being Tested

MR Prednisone IR Prednisone Placebo - MR Prednisone Placebo - IR Prednisone

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

PHASE3

The purpose of this study is to test in patients who have had hip replaceme...

Status

Terminated

Location

Multiple Locations

Start Date

2006-10

Trial ID

NCT00364533

Treatments Being Tested

Tapentadol IR (CG5503)Placebo Oxycodone HCL IR Tapentadol IR (CG5503)

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

PHASE1

This is a 3 part, phase 1 crossover study in healthy subjects to evaluate t...

Status

Completed

Location

KalVista Investigative Site

Start Date

2020-05-19

Trial ID

NCT05118958

Treatments Being Tested

KVD824 Prototype 1 modified-release tablet KVD824 Prototype 2 modified-release tablet KVD824 Immediate-Release Capsule Placebo to KVD824 Prototype 1 KVD824 Prototype 3 modified-release tablet

COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

PHASE1

The purpose of this study is to assess, after single oral administration un...

Status

Withdrawn

Location

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit

Start Date

2015-05

Trial ID

NCT02395237

Treatments Being Tested

: Amaryl® M IR 2/1000

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

PHASE1

The main objective of this trial is to select a formulation principle (tabl...

Status

Terminated

Location

Quotient Sciences

Start Date

2020-02-25

Trial ID

NCT04232839

Treatments Being Tested

BI 894416 Reference Formulation BI 894416 Formulation A2 BI 894416 Formulation C2 BI 894416 Formulation D2 BI 894416 Formulation F2

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

PHASE1

The study is designed to understand the blood concetration of PF-06412562 a...

Status

Completed

Location

Pfizer Clinical Research Unit

Start Date

2014-09

Trial ID

NCT02201511

Treatments Being Tested

3 mg PF-06412562 MR tablets_Fasted 2 x 15 mg PF-06412562 MR tablets_Fasted 2 x 15 mg PF-06412562 MR tablets_Fed 10 mg PF-06412562 IR tablets

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

PHASE1

This clinical trial is being conducted to compare concentrations of hydroco...

Status

Withdrawn

Location

US001: PRA Health Sciences

Start Date

2017-09

Trial ID

NCT03137030

Treatments Being Tested

GRT7014 - Abuse Deterrend Tablet Norco 5Mg-325Mg Tablet

To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).

PHASE1

As a transition from preclinical investigations to clinical development in ...

Status

Terminated

Location

1284.1.1 Boehringer Ingelheim Investigational Site

Start Date

2010-05

Trial ID

NCT01145014

Treatments Being Tested

BI 660848 BI 660848 BI 660848 BI 660848 BI 660848 BI 660848 BI 660848 BI 660848 BI 660848 BI 660848 BI 660848 Placebo

A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

PHASE1

Researchers are looking for a better way to treat heart failure, a conditio...

Status

Completed

Location

SocraTec R&D GmbH

Start Date

2021-10-12

Trial ID

NCT05086952

Treatments Being Tested

Vericiguat (BAY1021189) - Intervention A Vericiguat (BAY1021189) - Intervention B Vericiguat (BAY1021189) - Intervention C Vericiguat (Verquvo, BAY1021189) - Intervention D

Previous Next